Search

Competing Interests: Conflicts of interest Dr Lara-Corrales has received honoraria from Pierre Fabre, Amgen, Ipsen, Novartis, Pfizer, and Sanofi Genzyme and grants from AbbVie, Janssen, Clementia, Eli Lilly, Mayne Pharma, and Sanofi Genzyme. Dr Liy-Wong is advisor for Sanofi, Bayer, and Pfizer. Dr McKenzie is advisor for AbbVie, Amgen, Bausch, Bristol-Myers, Celgene, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, Sun Pharma, and UCB. Dr Rieder is advisor/consultant for, has received grants/honoraria from, and/or has served as a speaker for LEO Pharma, Pfizer, and Sanofi Genzyme. Drs Martinez-Cabriales, Coulombe, Aaron, Hussain, Linggonegoro, Barootes, Brandling-Bennett, Covelli, Kirkorian, Shah, Castelo-Soccio, Arkin, Heinze, Travis, Del Pozzo-Magana, Schoch, Monir, Glick, Uwakwe, Skillman, Hekman, Lethebe, and Ramien have no conflicts of interest to declare.

Background: Infantile hemangiomas (IHs) of the anogenital region remain poorly characterized., Objective: To examine the distribution, ulceration rate, and associated congenital anomalies of anogenital IHs., Methods: Retrospective study at 8 tertiary referral centers., Results: A total of 435 infants with an IH of the anogenital region were enrolled (of which, 319 [73%] were girls). Congenital anomalies were present in 6.4% (n = 28) of infants with an anogenital IH. Segmental or partial segmental anogenital IHs ulcerated in 72% (n = 99 of 138) of infants, whereas 45% (n = 133 of 297) of focal anogenital IHs experienced ulceration (P < .001). In a multivariable logistic regression analysis, segmental or partial segmental morphology (adjusted odds ratio [aOR], 2.70; 95% CI, 1.60-4.64), mixed type (aOR, 3.44; 95% CI, 2.01-6.07), and perianal (aOR, 3.01; 95% CI, 1.53-6.12) and buttocks location (aOR, 2.08; 95% CI, 1.17-3.76) had increased odds of ulceration. Segmental or partial segmental IHs of the genitalia were confined to distinct anatomic territories and were predominantly distributed unilaterally, with a linear demarcation at the perineal raphe., Limitations: Possible selection bias, given recruitment at tertiary referral centers., Conclusion: This study improves our understanding of high-risk features of anogenital IHs and demonstrates that genital segmental or partial segmental IHs develop within distinct anatomic territories., Competing Interests: Conflicts of interest Dr Faith is a consultant for Verrica Pharmaceuticals, Novartis, and Canfield Scientific. Other authors have no conflicts of interest to declare., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Background: Neurofibromatosis type 1 (NF-1) predisposes individuals to the development of benign and malignant tumors. The association of NF-1, juvenile xanthogranuloma (JXG), and juvenile myelomonocytic leukemia has been described in the literature. It is unclear whether JXG alone constitute a risk factor for leukemia or other malignancies in children with NF-1., Objective: To determine if there is an association between NF-1, JXG, and malignancy., Methods: We conducted a retrospective case-control study comparing children with NF-1 and malignancy (cases) with sex- and age-matched children with NF-1 without malignancy (controls)., Results: We identified 739 patients with NF-1 over a 20-year period, 14 of whom also had a diagnosis of malignancy. These cases include 9 (64%) boys and 5 (36%) girls. JXG were found in 4/14 (28.5%) cases and 6/29 (21%) controls (odds ratio 1.5, 95% confidence interval 0.35-6.6, P = .56)., Limitations: Retrospective design, small number of cases, and inconsistent documentation of clinical findings, including age at disappearance of JXG., Conclusions: Juvenile xanthogranulomas do not appear to confer an increased risk for malignancy in children with NF-1., (Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Hidradenitis suppurativa (HS) generally appears after puberty, is infrequently seen in younger children, and early onset, which is associated with more widespread disease, is more common in children with a positive family history of HS. When compared with adults with HS, children with HS are more likely to have hormonal imbalances, making hormonal investigations integral to disease management in pediatric patients. HS affects intertriginous areas, presenting with double-ended comedones, tender subcutaneous nodules, purulent discharge, and the formation of sinus tracts, hypertrophic fibrotic scars, and dermal contractures. Treatment of HS in children has not been well studied. The goals of therapy in the pediatric setting are to alleviate pain, minimize inflammation and scarring, prevent disease progression, and postpone the need for surgery. Mild cases can be treated with topical antibiotics, while topical and oral antibiotics are the primary therapies for moderate forms of HS. Modalities like biologic agents, laser therapy, or surgery have been reserved for severe pediatric cases of HS. Early recognition and treatment are critical to minimize the effects of the disease on the life course. Given the significant impact of the condition on quality of life and self-esteem, there is a clear role for psychological support., (Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)